	US 12,228,578 B2
	Rocky mountain spotted fever detection and treatment
Joshua Michael Boucher, Gray, ME (US); Anton Mestek, Jr., Gorham, ME (US); Clever Madrid, Cumberland, ME (US); and Jesse Stephen Buch, Kennebunk, ME (US)
Assigned to IDEXX LABORATORIES, INC., Westbrook, ME (US)
Filed by IDEXX LABORATORIES, INC., Westbrook, ME (US)
Filed on Dec. 17, 2021, as Appl. No. 17/554,557.
Claims priority of provisional application 63/126,756, filed on Dec. 17, 2020.
Prior Publication US 2022/0196672 A1, Jun. 23, 2022
Int. Cl. G01N 33/68 (2006.01); C07K 14/29 (2006.01); G01N 33/569 (2006.01)

CPC G01N 33/6854 (2013.01) [C07K 14/29 (2013.01); G01N 33/56911 (2013.01); C07K 2319/02 (2013.01); C07K 2319/30 (2013.01); G01N 2333/29 (2013.01); G01N 2469/20 (2013.01)]

23 Claims

1. A polypeptide comprising:

(i) 90% or more sequence identity to the polypeptide as set forth in SEQ ID NO: 3, 4, 5, 6, or 7;

(ii) a fusion protein comprising two, three, four, five, six, seven or more polypeptides having 90% or more sequence identity to SEQ ID NO:1, 2, 3, 4, 5, 6, or 7; or

(iii) a fusion protein comprising at least two polypeptides having 90% or more sequence identity to SEQ ID NO: 3, 4, 5, 6, or 7;

(iv) the polypeptide as set forth in SEQ ID NO:1 or 2.